Skip to main content
. Author manuscript; available in PMC: 2012 Mar 6.
Published in final edited form as: Cancer Res. 2005 Jun 1;65(11):4747–4753. doi: 10.1158/0008-5472.CAN-05-0018

Fig. 1. Binding of MAGE-D1 and BRCA2.

Fig. 1

(A). Diagram of BRCA2 mutants. The binding of BRCA2 and its mutants to MAGE-D1 is summarized.

(B). In vivo binding of BRCA2 and MAGE-D1. 293T cells were transfected with Myc-tagged full-length MAGE-D1 and Flag-tagged BRCA2 and its mutants. The cells were harvested 48 hours after transfection in LSAB. BRCA2 and its mutants were immunoprecipitated using anti-Flag antibody. The immunoprecipitated protein complexes were fractionated and immunoblotted using anti-Myc antibody (9E10) to detect Myc-MAGE-D1. The blot was re-probed using anti-Flag antibody to detect BRCA2 and its mutants. A 4% (right panel) and a 7.5% (left panel) PAGE gels were used to fractionate the full-length BRCA2 and its mutants of varied molecular weight (from 58kd-380kd).